vial of 0.1 mL concentrate (484R-14), vial of 0.1 mL concentrate Research Use Only (484R-14-RUO), vial of 0.5 mL concentrate (484R-15), vial of 1.0 mL concentrate (484R-16), vial of 1.0 mL concentrate Research Use Only (484R-16-RUO), vial of 1.0 mL pre-dilute Research Use Only (484R-17-RUO), vial of 1.0 mL pre-dilute ready-to-use (484R-17), vial of 25.0 mL pre-dilute ready-to-use Research Use Only (484R-10-RUO), vial of 25.0 mL pre-dilute ready-to-use (484R-10), vial of 7.0 mL pre-dilute ready-to-use (484R-18), vial of 7.0 mL pre-dilute ready-to-use Research Use Only (484R-18-RUO)
PRAME (PReferentially-expressed Antigen in MElanoma) is a gene encoded on the 22q11-22 chromosomal sequence and encodes a 509 amino acid residue protein.1 PRAME is a melanoma antigen that is preferentially expressed in tumors and is recognized by cytotoxic T lymphocytes.2,3 PRAME can be used to distinguish between malignant melanoma cells and nevus cells,4 and therefore may be useful for diagnostic purposes to support a suspected case of melanoma. PRAME is considered a cancer-testis antigen (CTA)5 and is not strongly expressed in most other normal tissues. PRAME is positively expressed in about half of uveal melanomas,6 and the majority of mucosal melanomas.7
Physical form
Solution in Tris Buffer, pH 7.3-7.7, with 1% BSA and < 0.1% Sodium Azide.